These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 677139)

  • 41. A vancomycin drug use evaluation and economic analysis in a cancer treatment centre.
    Dranitsaris G; Pilla NJ; McGreer A
    Can J Hosp Pharm; 1994 Apr; 47(2):59-64. PubMed ID: 10134128
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An approach to cost-effective antibiotic utilization.
    Venezio FR; Waitley DW
    Hosp Formul; 1988 Dec; 23 Suppl D():32-5. PubMed ID: 10312796
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of ampicillin-sulbactam before and after formulary inclusion.
    Koch KE; Taylor MR
    Am J Hosp Pharm; 1991 Jul; 48(7):1492-6. PubMed ID: 1882880
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prophylactic antibiotics in abdominal hysterectomy.
    Tanos V; Rojansky N
    J Am Coll Surg; 1994 Nov; 179(5):593-600. PubMed ID: 7952465
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multidisciplinary approach to cost reduction of C-section prophylaxis.
    Todd MW; Benrubi G
    Hosp Formul; 1990 Apr; 25(4):446-8, 450. PubMed ID: 10104235
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prophylactic antibiotics for non-laboring patients with intact membranes undergoing cesarean delivery: an economic analysis.
    Chelmow D; Hennesy M; Evantash EG
    Am J Obstet Gynecol; 2004 Nov; 191(5):1661-5. PubMed ID: 15547539
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost analysis of using premixed frozen versus hospital-reconstituted cefazolin sodium injection.
    Havlovic DA; Ivey MF; Grotzinger RP
    Am J Hosp Pharm; 1987 Apr; 44(4):783-7. PubMed ID: 3578311
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Application of decision analysis to drug selection for formulary addition.
    Kresel JJ; Hutchings HC; MacKay DN; Weinstein MC; Read JL; Taylor-Halvorsen K; Ashley H
    Hosp Formul; 1987 Jul; 22(7):658-63, 673, 676. PubMed ID: 10282682
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Controlling cephalosporin and aminoglycoside costs through pharmacy and therapeutics committee restrictions.
    Hayman JN; Sbravati EC
    Am J Hosp Pharm; 1985 Jun; 42(6):1343-7. PubMed ID: 4014250
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative costs of two cephalosporins, cefazolin and cephalothin.
    Klimek JJ; Cunha BA; Quintiliani R
    Drug Intell Clin Pharm; 1976 Nov; 10(11):655. PubMed ID: 10236221
    [No Abstract]   [Full Text] [Related]  

  • 51. Formulary decisions concerning cephalosporins.
    Fuentes RJ
    Am J Hosp Pharm; 1979 Mar; 36(3):296, 300. PubMed ID: 420220
    [No Abstract]   [Full Text] [Related]  

  • 52. Economic analysis of a new drug: potential savings in hospital operating costs from the use of a once-daily regimen of a parenteral cephalosporin.
    Eisenberg JM; Koffer H; Finkler SA
    Rev Infect Dis; 1984; 6 Suppl 4():S909-23. PubMed ID: 6441226
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Selection of cephalosporins for hospital formularies.
    Wilson WR
    Diagn Microbiol Infect Dis; 1995; 22(1-2):129-34. PubMed ID: 7587026
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The simultaneous quantitative determination of cephalothin and cefazolin in serum by high pressure liquid chromatography.
    Wold JS; Turnipseed SA
    Clin Chim Acta; 1977 Jul; 78(2):203-7. PubMed ID: 884857
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cephalosporin utilisation review and evaluation.
    Misan GM; Dollman C; Shaw DR; Burgess N
    Pharmacoeconomics; 1995 Aug; 8(2):100-22. PubMed ID: 10155606
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Formulary decision-making about cephalosporins with similar therapeutic uses.
    Mabe DM
    Am J Health Syst Pharm; 2003 May; 60(10 Suppl 1):S12-5. PubMed ID: 12789882
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Third generation cephalosporins in the parenteral to oral switch.
    Rimmer D
    Pharmacoeconomics; 1994; 5(Suppl 2):27-33. PubMed ID: 10147286
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hospital formularies: need for continuous intervention.
    Feely J; Chan R; Cocoman L; Mulpeter K; O'Connor P
    BMJ; 1990 Jan; 300(6716):28-30. PubMed ID: 2105122
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of water content on the solid-state stability in two isomorphic clathrates of cephalosporin: cefazolin sodium pentahydrate (alpha form) and FK041 hydrate.
    Mimura H; Gato K; Kitamura S; Kitagawa T; Kohda S
    Chem Pharm Bull (Tokyo); 2002 Jun; 50(6):766-70. PubMed ID: 12045330
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New drugs and clinical economics: analysis of cost effectiveness in the assessment of pharmaceutical innovations.
    Eisenberg JM
    Rev Infect Dis; 1984; 6 Suppl 4():S905-8. PubMed ID: 6441225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.